Compare Gilead Sciences, Inc. (GILD) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Gilead Sciences, Inc. trades at $133.04 (market cap $163.51B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $411.03 (market cap $1.96T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 12× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TSM | |
|---|---|---|
Market Cap | $163.51B | $1.96T |
Sector | Health | Technology |
52-Week High | $155.80 | $477.57 |
52-Week Low | $108.22 | $227.33 |
Enterprise Value | $178.05B | $1.89T |
Dividend Yield | 2.49% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Taiwan Semiconductor Manufacturing (TSM) trades at $420.39, down 0.28% on the day, amid a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 earnings with net profit surging 77% to NT$706.6 billion, beating estimates, driven by sustained AI chip demand. Key financials show a net income margin of 46.5% and ROE of 36.51%, with revenue growth accelerating to $3.81 trillion in 2025. Analyst consensus is bullish with a $498.33 price target, though technical indicators highlight near-term resistance at $425.
TSM's outlook remains positive due to AI-driven demand and earnings momentum, but risks include geopolitical tensions and high valuation multiples. The stock offers growth potential with a 18% upside to the consensus target, yet investors should monitor competitive pressures and macroeconomic volatility. Strong cash flow and dividend payments support shareholder returns, but the bearish technical trend warrants caution for short-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
